Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Histone Deacetylase Inhibitor Romidepsin Inhibits<i>De Novo</i>HIV-1 Infections

21 Apr 2015

Abstract excerpt

Adjunct therapy with the histone deacetylase inhibitor (HDACi) romidepsin increases plasma viremia in HIV patients on combination antiretroviral therapy (cART). However, a potential concern is that reversing HIV latency with an HDACi may reactivate the virus in anatomical compartments with suboptimal cART concentrations, leading to de novo infection of susceptible cells in these sites. We tested physiologically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine and Purinergic Signaling
Share to HIV-related health complications and treatments
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25896701
DOI: 10.1128/aac.00574-15

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Histone Deacetylase Inhibitor Romidepsin Inhibits<i>De Novo</i>HIV-1 InfectionsPMID 25896701Read ↗

The Depsipeptide Romidepsin Reverses HIV-1 Latency In VivoSemantic proximity Read ↗

Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations.Semantic proximity Read ↗

Inhibition of ALKBH5 demethylase of m6A pathway potentiates HIV-1 reactivation from latencySemantic proximity Read ↗

Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individualsSemantic proximity Read ↗

In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase InhibitorsSemantic proximity Read ↗

HIV latency: experimental systems and molecular modelsSemantic proximity Read ↗

Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8+T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency ReversalSemantic proximity Read ↗

Human endogenous retrovirus (HERV) expression is not induced by treatment with the histone deacetylase (HDAC) inhibitors in cellular models of HIV-1 latencySemantic proximity Read ↗

Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinationsSemantic proximity Read ↗

Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trialSemantic proximity Read ↗

Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirsSemantic proximity Read ↗

Therapy for Latent HIV-1 Infection: The Role of Histone Deacetylase InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.